Immunologic Factor
FDA Pauses BioNTech’s Malaria Vaccine Trial Amid Regulatory Scrutiny
BioNTech, malaria vaccine, FDA clinical hold, RNA vaccine, regulatory challenges
Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi
Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia
Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer
Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup
Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach
Johnson & Johnson, Samsung Bioepis, Stelara, biosimilar, lawsuit, contract breach, ustekinumab, Pyzchiva
Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations
Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials
CDC Vaccine Advisory Committee Meeting Postponed Following RFK Jr.’s Confirmation as HHS Secretary
ACIP, CDC, vaccine recommendations, Robert F. Kennedy Jr., HHS, postponement, public health, immunization policy
GSK’s Penmenvy Approved: New 5-in-1 Meningococcal Vaccine Enters U.S. Market
Penmenvy, GSK, meningococcal vaccine, FDA approval, 5-in-1 vaccine, MenABCWY, invasive meningococcal disease (IMD)
Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up
Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers
Biotech Breakthroughs 2025: Emerging Trends and Technologies Shaping the Industry’s Future
CRISPR therapeutics, solid-state batteries, precision medicine, AI in drug discovery, gene editing, cancer vaccines, personalized therapies, biotech investment, platform technologies, clinical trial innovation
GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market
Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults